Targeted Therapies in Cancer

From its introduction, oncological chemotherapy has been encumbered by its poor selectivity because most antiproliferative drugs are toxic not only to tumor cells but also to important populations of the body’s non-neoplastic cells. The resultant problems with unwanted side effects are compounded by...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Συγγραφή απο Οργανισμό/Αρχή: SpringerLink (Online service)
Άλλοι συγγραφείς: Dietel, Manfred (Επιμελητής έκδοσης)
Μορφή: Ηλεκτρονική πηγή Ηλ. βιβλίο
Γλώσσα:English
Έκδοση: Berlin, Heidelberg : Springer Berlin Heidelberg, 2007.
Σειρά:Recent Results in Cancer Research, 176
Θέματα:
Διαθέσιμο Online:Full Text via HEAL-Link
LEADER 04241nam a22004575i 4500
001 978-3-540-46091-6
003 DE-He213
005 20151204141349.0
007 cr nn 008mamaa
008 100301s2007 gw | s |||| 0|eng d
020 |a 9783540460916  |9 978-3-540-46091-6 
024 7 |a 10.1007/978-3-540-46091-6  |2 doi 
040 |d GrThAP 
050 4 |a RC254-282 
072 7 |a MJCL  |2 bicssc 
072 7 |a MED062000  |2 bisacsh 
082 0 4 |a 616.994  |2 23 
245 1 0 |a Targeted Therapies in Cancer  |h [electronic resource] /  |c edited by Manfred Dietel. 
264 1 |a Berlin, Heidelberg :  |b Springer Berlin Heidelberg,  |c 2007. 
300 |a XIV, 262 p.  |b online resource. 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
347 |a text file  |b PDF  |2 rda 
490 1 |a Recent Results in Cancer Research,  |x 0080-0015 ;  |v 176 
505 0 |a Prediction of Tumor Behavior -- Beyond Typing and Grading: Target Analysis in Individualized Therapy as a New Challenge for Tumour Pathology -- Oncogenic Signaling Pathways and Deregulated Target Genes -- Predictive Pathology of Cytostatic Drug Resistance and New Anti-cancer Targets -- Prediction of Response to Neoadjuvant Chemotherapy in Carcinomas of the Upper Gastrointestinal Tract -- Resistance-Associated Signatures in Breast Cancer -- Resistance to Chemotherapy in Ovarian Carcinoma -- Clinical, Biological, and Molecular Aspects of Metastasis in Colorectal Cancer -- Prediction of Efficacy and Side Effects of Chemotherapy in Colorectal Cancer -- Proteomic Expression Profiling of Breast Cancer -- Targeted Therapy and Clinical Applications -- Targeted Therapy and Blood-Brain Barrier -- Cetuximab: Appraisal of a Novel Drug Against Colorectal Cancer -- C-kit, GIST, and Imatinib -- Antibody Therapy in Non-Hodgkin’s Lymphoma: The Role of Rituximab, 90Y-Ibritumomab Tiuxetan, and Alemtuzumab -- Molecular and Clinical Aspects of Proteasome Inhibition in the Treatment of Cancer -- Individualized Target Therapy of Malignant Lymphomas: An Outlook -- Antiangiogenesis, Anti-VEGF(R) and Outlook -- Morphological Detection of Hormone and Growth Factor Receptors in Breast Cancer -- Prospects for Development -- Antigen-Specific Cancer Vaccines -- Therapeutic Vaccination for the Treatment of Malignant Melanoma -- Monoclonal and Recombinant Antibodies with T Cell Receptor-Like Reactivity -- New Molecular Therapy Targets in Acute Myeloid Leukemia. 
520 |a From its introduction, oncological chemotherapy has been encumbered by its poor selectivity because most antiproliferative drugs are toxic not only to tumor cells but also to important populations of the body’s non-neoplastic cells. The resultant problems with unwanted side effects are compounded by difficulties in predicting the desired effectivity of chemotherapy in individual patients. This unsatisfactory situation has driven intensive research and development towards more specific and less toxic anticancer drugs over the last few decades. Several results of these efforts have reached the clinic and an even greater number are now in preclinical testing. Common to all these targeted therapies is their interaction with defined molecules present on cancer cells, which adds various degrees of increased selectivity to their toxic effects. As a consequence, detecting the target molecule on tumors before therapy holds great diagnostic potential for predicting the efficacy of the drug and personalizing therapy. This book aims to present translational scientists and clinicians with an integrated critical view on the theories, mechanisms, problems and pitfalls of the targeted therapy approach. 
650 0 |a Medicine. 
650 0 |a Cancer research. 
650 0 |a Oncology. 
650 1 4 |a Medicine & Public Health. 
650 2 4 |a Oncology. 
650 2 4 |a Cancer Research. 
700 1 |a Dietel, Manfred.  |e editor. 
710 2 |a SpringerLink (Online service) 
773 0 |t Springer eBooks 
776 0 8 |i Printed edition:  |z 9783540460909 
830 0 |a Recent Results in Cancer Research,  |x 0080-0015 ;  |v 176 
856 4 0 |u http://dx.doi.org/10.1007/978-3-540-46091-6  |z Full Text via HEAL-Link 
912 |a ZDB-2-SME 
950 |a Medicine (Springer-11650)